News

Novo Nordisk has recruited 60,000 patients in the study and is expected to release the results of the multinational study in 2011. Novo Nordisk said that the insulin

Maxygen and Cangene have entered into an agreement in May 2009, under which Maxygen received from Cangene a non-refundable option fee of $500,000. As per the terms of

Novasep and instrAction said that the contract will offer a combination of instrAction’s proprietary API-selective stationary phases (Instruction Receptor Phase) and Novasep purification capabilities and high performance chromatography

Cellectis Bioresearch said that the new method, based on meganuclease-driven targeted integration, for the generation of stable cell lines, is compatible with HTS. Cellectis said that the development

Tamsulosin hydrochloride extended-release capsules are marketed under the trade names Flomax, Flomaxtra and Urimax, though generic non-modified release capsules are still approved and marketed in many countries, such

According to Apicore, the inspection was concluded successfully and it acts as a final milestone on the path to ANDA approval. Apicore said that following this milestone, Apicore

The HER-2 Study is led by the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences with Dr Yuankai Shi as the principal investigator. China Medical

The approach is designed to run on ZyGem’s new MicroLab platform. The company claimed that the platform has the potential to accurately identify up to 30 types of

Alcon is expected to use Varicent for core commission calculation in addition to scenario modeling, providing enhanced visibility into Alcon’s current and future sales quotas. Varicent is expected